John Bruch, MD
Endocrinology, Diabetes & Metabolism · Greenville, SCNPI 1447202023
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 9.8% — the pattern of someone who eats at a lot of different presentations.
Across 190 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$361
- Novo Nordisk$318
- Abbott$285
- BETA Bionics, Inc.$283
- Dexcom, Inc.$269
- Insulet Corporation$209
- plus $2K from 30 others
Across 1 payment — averaging $21,307 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$21K
What the payments were for
- Food & beverage$3,60398%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 18 | $361 |
| Novo Nordisk | 21 | $318 |
| Abbott | 13 | $285 |
| BETA Bionics, Inc. | 1 | $283 |
| Dexcom, Inc. | 31 | $269 |
| Insulet Corporation | 9 | $209 |
| Sanofi-aventis U.S. LLC | 10 | $205 |
| Xeris Pharmaceuticals, Inc. | 7 | $140 |
| Tandem Diabetes Care, Inc. | 5 | $137 |
| Corcept Therapeutics | 5 | $130 |
| Medtronic(2 entities) | 4 | $126 |
| Amgen | 7 | $118 |
| AbbVie | 7 | $102 |
| Boehringer Ingelheim | 6 | $96 |
| Radius Health, Inc. | 3 | $77 |
| Pfizer | 4 | $72 |
| Lifescan, Inc. | 4 | $67 |
| Novartis | 3 | $66 |
| Madrigal Pharmaceuticals | 2 | $56 |
| AstraZeneca(2 entities) | 3 | $55 |
| Cequr Corporation | 3 | $53 |
| Amneal Pharmaceuticals LLC | 3 | $51 |
| Antares Pharma, Inc. | 3 | $49 |
| Chiesi USA, Inc. | 2 | $49 |
| Sequel Med Tech, LLC | 2 | $42 |
| Ascensia Diabetes Care US Inc. | 2 | $38 |
| BD | 2 | $35 |
| Mannkind Corporation | 2 | $34 |
| Zealand Pharma US, Inc. | 1 | $26 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| Intuity Medical Inc | 1 | $24 |
| Embecta Corp. | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Valeritas, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,687 in reported general payments places this provider in the 55th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
See all endocrinology, diabetes & metabolism providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 229 | $245,518 |
| JardianceEmpagliflozin | 167 | $161,299 |
| Tresiba Flextouch U-200Insulin Degludec | 82 | $110,169 |
| Humalog Kwikpen U-200Insulin Lispro | 43 | $102,674 |
| TrulicityDulaglutide | 76 | $95,693 |
| MounjaroTirzepatide | 66 | $75,843 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $43,567 |
| Novolog FlexpenInsulin Aspart | 111 | $42,867 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $35,262 |
| FarxigaDapagliflozin Propanediol | 36 | $33,449 |
| Tresiba Flextouch U-100Insulin Degludec | 55 | $30,516 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 49 | $25,420 |
| Humalog Kwikpen U-100Insulin Lispro | 100 | $24,077 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 166 | $23,809 |
| NovologInsulin Aspart | 65 | $21,458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $318 | $266,976294 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $361 | $189,943188 claims |
| Boehringer IngelheimJardiance | $96 | $161,299167 claims |
| AstraZenecaFarxiga | $55 | $33,44936 claims |
| AbbVieSynthroid | $102 | $11,708144 claims |
| PfizerLevoxyl | $72 | $8,072184 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $51 | $7,889676 claims |
| Sanofi-aventis U.S. LLCLantus | $205 | $5,11349 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.
Other endocrinology, diabetes & metabolism in Greenville
- Cory WhiteGreenville$413K
- James HortonGreenville$73K
- Mojgan RahmaniyanGreenville$6K
- Sandra WeberGreenville$5K
- Gregory SchleisGreenville$2K
- Gauri DhirMyrtle Beach$417K
- Louis HaenelCharleston$377K
- Vonda CalcuttWalterboro$368K
- Ray VaughtersAiken$321K
- Donald EagertonMyrtle Beach$284K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.